| abstract |
The present application includes systemic (e.g. intravenously or subcutaneously) administration of an effective amount of a composition comprising nanoparticles comprising an mTOR inhibitor (such as a limus drug such as sirolimus or a derivative thereof) and albumin to a subject. And, optionally, administering a second agent (such as an anti-VEGF antibody, proteasome inhibitor, or alkylating agent), a method of treating a CNS disorder (such as glioblastoma and epilepsy) in an individual. |